Advertisement

Maternal Use of Antidepressants and Infant Congenital Malformations

  • Bengt Källén
Chapter

Abstract

During the observation period an increasing proportion of pregnant women have used antidepressants in early pregnancy, notably selective serotonin receptor inhibitors (SSRI). Studied as a group, little teratogenic properties appear which argues for only little if any general confounding by indication. For clomipramine, a risk appears to exist consisting of an increased risk of cardiovascular defects. Among SSRI drugs two may be associated with such a risk: paroxetine and possibly fluoxetine. The results vary between different studies and may be due to different dosages used or even differences in population pharmacogenetics. So far no certain teratogenic effect has been demonstrated for serotonin/noradrenalin receptor inhibitors but more data are needed. If possible the two most suspected drugs (clomipramine and paroxetine) should be avoided but if exposure has already occurred, the risk is only moderately high and the involved cardiac defects are usually not very serious. Some associations with other malformations have been suggested but cannot be looked upon as definite.

References

  1. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356:2684–92.CrossRefGoogle Scholar
  2. Andrade SE, Rachel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198:194.e1–5.CrossRefGoogle Scholar
  3. Ban L, Gibson JE, West J, Fiaschi L, Sokal R, Smeeth L, Doyle P, Hubbard RB, Tata LJ. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. BJOG. 2014;121:1471–81.CrossRefGoogle Scholar
  4. Bérard A, Ramos É, Rey É, Blais L, St.-André M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80:18–27.CrossRefGoogle Scholar
  5. Bérard A, Zhao J-P, Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec pregnancy cohort. BMJ Open. 2017;7:e013372.  https://doi.org/10.1136/bmjopen-2016-013372.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Biswas PN, Wilton LV, Shakir SA. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study of 13554 patients in England. J Psychopharmacol. 2003;17:121–6.CrossRefGoogle Scholar
  7. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010–5.CrossRefGoogle Scholar
  8. Cole A, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:1075–85.CrossRefGoogle Scholar
  9. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol. 2011;91:142–52.CrossRefGoogle Scholar
  10. Danielsson C, Brask J, Sköld A-C, Genead R, Andersson A, Andersson U, Stockling K, Pehrson R, Grinnermo K-H, Salari S, Hellmold H, Danielsson B, Sylvén C, Elindeer F. Exploration of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel block as a common teratogenic mechanism. Cardiovasc Res. 2013;97:23–32.CrossRefGoogle Scholar
  11. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, Ulcickas M, Platt R. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16:1086–94.CrossRefGoogle Scholar
  12. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A. Paroxetine and fluoxetine in pregnancy: a prospective, multicenter, controlled, observational study. Br J Clin Pharmacol. 2008;66:695–705.PubMedPubMedCentralGoogle Scholar
  13. Djulus J, Koren G, Einarson TR, Wilton L, Shakir S, Diav-Citrin O, Kennedy D, Voyer Lavigne S, De Santis M, Einarson A. Exposure to mirtazapine during pregnancy: a prospective comparative study of birth outcomes. J Clin Psychiatry. 2006;67:1280–4.CrossRefGoogle Scholar
  14. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Broshu J, Chambeers C, Mastroiacovo P, Addis A, Matsui D, Shuler L, Einarson TR, Koren G. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001;158:1728–30.CrossRefGoogle Scholar
  15. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, Kennedy D, Einarson TR, Koren G. Evaluation of the risk of congenital cardiovascular defects associated with the use of paroxetine during pregnancy. Am J Psychiatry. 2008;165:749–52.CrossRefGoogle Scholar
  16. Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy, results of a large prospective cohort study. Can J Psychiatr. 2009;54:242–6.CrossRefGoogle Scholar
  17. Einarson A, Choi J, Koren G, Einarson T. Outcomes of infants exposed to multiple antidepressants during pregnancy: results of a cohort study. J Popul Ther Clin Pharmacol. 2011;18:e390–6.PubMedGoogle Scholar
  18. Ericson A, Källén B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 1999;55:503–8.CrossRefGoogle Scholar
  19. Furu K, Haglund B, Engeland A, Selmer R, Stephansson O, Valdimarsdottir UA, Zoega H, Artama M, Gissler M, Malm H, Nørgaard M. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015;350:h1798.  https://doi.org/10.1136/bmj/h1798.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Goldstein DJ, Corbin LA, Sundell KI. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol. 1997;89:713–8.CrossRefGoogle Scholar
  21. Hoog SL, Cheng Y, Elpers J, Dowsett SA. Duloxetine and pregnancy outcome: safety surveillance findings. Int J Med Sci. 2013;10:413–9.CrossRefGoogle Scholar
  22. Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Homes LB, Franklin JM, Mogun H, Levin R, Kowal JM, Setogushi S, Hernandez-Diaz S. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370:2397–407.CrossRefGoogle Scholar
  23. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S, Gislason GH, Torp-Pedersen C, Poulsen HE. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open. 2012;2:e001148.  https://doi.org/10.1136/bmjopen-2012-001148.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Jordan S, Morris JK, Davies GI, Tucker D, Thayer DS, Luteljn JM, Morgan M, Garne E, Hansen AV, Klungsøyr K, Engeland A, Boyle B, Dolk H. Selective serotonin reuptake inhibitor (SSRI) antidepressants in pregnancy and congenital anomalies: analysis of linked databases in Wales, Norway and Funen, Denmark. PLoS One. 2016;11:e0165122.  https://doi.org/10.1371/journal-pone.0165122.CrossRefPubMedPubMedCentralGoogle Scholar
  25. Källén B. The safety of antidepressant drugs during pregnancy. Expert Opin Drug Saf. 2007;6:357–70.CrossRefGoogle Scholar
  26. Källén B, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol. 2003;17:255–61.CrossRefGoogle Scholar
  27. Källén B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defects. Letter to the editor. Reprod Toxicol. 2006;21:221–2.CrossRefGoogle Scholar
  28. Källén BAJ, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79:301–8.CrossRefGoogle Scholar
  29. Källén B, Borg N, Reis N. The use of central nervous system active drugs during pregnancy. Pharmaceuticals. 2013;6:1221–86.CrossRefGoogle Scholar
  30. Knudsen TM, Hansen AV, Garne E, Nybo Andersen A-M. Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy—an epidemiological study using validated EUROCAT data. BMC Pregnancy Childbirth. 2014;14:333. http://www.biomedcentral.com/1471-2392/14/333.CrossRefGoogle Scholar
  31. Kornum JB, Nielsen RH, Pedersen L, Mortensen PB, Nørgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol. 2010;2:29–36.CrossRefGoogle Scholar
  32. Kulin NA, Pastuszak A, Sage SR, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy. Prospective comparative evaluation of pregnancy and fetal outcome. JAMA. 1998;279:609–10.CrossRefGoogle Scholar
  33. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007;27:607–13.CrossRefGoogle Scholar
  34. Louik C, Lin AE, Werler MM, Hernández-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356:26575–2683.CrossRefGoogle Scholar
  35. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005;106:1289–96.CrossRefGoogle Scholar
  36. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011;118:111–20.CrossRefGoogle Scholar
  37. McBride WG. The teratogenic effect of imipramine. Teratology. 1972;5:262.Google Scholar
  38. McElhatton PR, Garbis HM, Eléfant E, Vial T, Bellemin B, Mastroiacovo P, Arnon J, Rodríguez-Pinilla E, Schaefer C, Pexieder T, Merlob P, Verme SD. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol. 1996;10:285–94.CrossRefGoogle Scholar
  39. Nembhard WN, Tang X, Hu S, MacLeod S, Stowe Z, Webber D. Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors, and risk of congenital heart defects in offspring: population based study. BMJ. 2017;356:j832.  https://doi.org/10.1136/bmj.j832.CrossRefPubMedPubMedCentralGoogle Scholar
  40. Nielsen SW, Møller Ljugndahl P, Nielsen J, Mertz-Nørgård B, Qvist N. Maternal use of selective serotonin reuptake inhibitors during pregnancy is associated with Hirschsprung’s disease in newborns—a nationwide cohort study. Orphanet J Rare Dis. 2017;12:116.  https://doi.org/10.1186/s13023-017-0667-4.CrossRefPubMedPubMedCentralGoogle Scholar
  41. Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M. Pregnancy outcome after exposure to antidepressants and the role of maternal depression. J Clin Psychopharmacol. 2012;32:186–94.CrossRefGoogle Scholar
  42. Oberland TF, Warburton A, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008;83:68–76.CrossRefGoogle Scholar
  43. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli P, Sinn S, Donnenfeld A, McComack M, Leen-Mitchell M, Woodland C, Gardner A, Horn M, Koren G. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269:2246–8.CrossRefGoogle Scholar
  44. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339:B3569.  https://doi.org/10.1136/bmj.b3569.CrossRefPubMedPubMedCentralGoogle Scholar
  45. Polen KND, Rasmussen SA, Riehle-Colarusso T, Reefhuis J. Association between reported venlafaxine use in early pregnancy and birth defects. National Birth Defects Prevention Study 1997-2007. Birth Defects Res A Clin Mol Teratol. 2013;97:28–34.CrossRefGoogle Scholar
  46. Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ. 2015;350:h3190.  https://doi.org/10.1136/bmj.h3190.CrossRefGoogle Scholar
  47. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy. An update using Swedish data. Psychol Med. 2010;10:1723–33.CrossRefGoogle Scholar
  48. Reis M, Källén B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe malformations or cardiac defects. A register study. BMJ Open. 2013;3:e002166.  https://doi.org/10.1136/bmjopen-2012-002166.CrossRefPubMedPubMedCentralGoogle Scholar
  49. Simon GE, Cunningham ML, Davis RL. Outcome of prenatal antidepressant exposure. Am J Psychiatry. 2002;159:2055–61.CrossRefGoogle Scholar
  50. Sivojelezova A, Shuhaltber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol. 2005;193:2004–9.CrossRefGoogle Scholar
  51. Vasilakis-Scaramozza C, Aschengrau A, Cabral H, Jick SS. Antidepressant use during early pregnancy and the risk of congenital anomalies. Pharmacotherapy. 2013;33:693–700.CrossRefGoogle Scholar
  52. Wemaker A, Casson K, Garne E, Bakker M, Addor M-C, Arriola L, Gatt M, Khoshnood B, Klungsoyr K, Nelen V, O’Mahoney M, Pierini A, Rissman A, Tucker D, Boyle B, de Jong-van den Berg L, Dolk H. Selective serotonin uptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study. Eur J Epidemiol. 2015;30:1187–98.CrossRefGoogle Scholar
  53. Wichman CL, Moore KM, Lang TR, St. Sauver JL, Heise RH Jr, Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 2009;84:23–7.CrossRefGoogle Scholar
  54. Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. Can Med Assoc J. 2005;173:1120.CrossRefGoogle Scholar
  55. Winterfeld U, Klinger G, Panchaud A, Stephens S, Arnon J, Malm H, Te Winkel B, Clementi M, Pistelli A, Maňácová E, Eleftherio G, Merlob P, Kaplan YC, Buclin T, Rothuizen LE. Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. J Clin Psychopharmacol. 2015;36:250–9.CrossRefGoogle Scholar
  56. Wogelius P, Nørgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Sørensen HT. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology. 2006;17:701–4.CrossRefGoogle Scholar
  57. Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E, Kalyoncu NI, Unsal M. Newer antidepressants in pregnancy: prospective comparative study of birth outcomes. Reprod Toxicol. 2004;19:235–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bengt Källén
    • 1
  1. 1.Tornblad Institute for Comparative EmbryologyLund UniversityLundSweden

Personalised recommendations